Gwenaëlle Gravis Mescam, MD, Institut Paoli Calmettes, Marseille, France, comments on the subset of patients with metastatic castration sensitive prostate cancer (mCSPC) who will benefit the most from the use of triplet therapy. The Phase III PEACE-1 trial (NCT01957436) established patients with low volume mCSPC had longer radiological progression-free survival (rPFS) when receiving abiraterone, prednisone and androgen deprivation therapy (ADT). The Phase III ARASENS trial (NCT02799602) additionally demonstrated darolutamide plus ADT and docetaxel to improve survival in patients. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.